Tovorafenib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Glioma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signalSingle-arm, accepted for approval (FDA label)

Also approved (1)
EU
  • Ojemda is indicated as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies (for biomarkers-based patient selection, see section 4.2)
Product first approved 2026EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Glioma
Phase 2 (5)
Glioma
NCT07206849 · Nationwide Children's Hospital
2027-02 – 2037-02 · High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV), Diffuse Intrinsic Pontine Glioma, High Grade Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma, Metastatic Brain Tumor
What this study did
Other / comorbidity
NCT05828069 · National Cancer Institute (NCI)
2024-03-28 – 2028-09-30 · Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
What this study did
NCT05465174 · Sabine Mueller, MD, PhD
2022-09-12 – 2028-03-01 · Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
What this study did
NCT04985604 · Day One Biopharmaceuticals, Inc.
2021-07-15 – 2024-07-08 · Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid Cancer, Papillary, Spitzoid Melanoma, Pilocytic Astrocytoma, Pilocytic Astrocytoma, Adult, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Colorectal Cancer, Pancreatic Acinar Carcinoma, Spitzoid Malignant Melanoma, Bladder Cancer, Bladder Urothelial Carcinoma, MAP Kinase Family Gene Mutation, RAF Mutation
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT06965114 · National Cancer Institute (NCI)
2026-05-29 – 2030-03-01 · Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia
What this study did
Phase 1 (7)
Glioma
NCT07441707 · Ipsen
2026-03-10 – 2030-07-31 · Low-grade Glioma
What this study did
NCT06381570 · Daniel Morgenstern
2024-03-21 – 2029-03-21 · Low-grade Glioma
What this study did
NCT03429803 · Karen D. Wright, MD
2018-02-27 – 2025-12-31 · Low-grade Glioma
What this study did
Other / comorbidity
NCT07121829 · Day One Biopharmaceuticals, Inc.
2022-05-02 – 2024-12-18 · Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, MAP Kinase Family Gene Mutation, RAS Mutation, RAF Mutation, MEK Mutation
What this study did
NCT01425008 · Millennium Pharmaceuticals, Inc.
2011-09-15 – 2018-10-16 · Melanoma, Metastatic Melanoma, Solid Tumor, Neoplasm
What this study did
NCT02327169 · Millennium Pharmaceuticals, Inc.
2015-01-14 – 2018-07-02 · Advanced Nonhematologic Malignancies
What this study did

Competitive landscape

This drug's own stage for Glioma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tovorafenib: this drugApprovedSmall moleculeKinase InhibitorWeak signalNo reviewed efficacy summary in this indication
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)not yet gradedNo reviewed efficacy summary in this indication
DordaviproneApprovedSmall moleculeMitochondrial caseinolytic protease P (ClpP), Dopamine D2 receptorWeak signalNo reviewed efficacy summary in this indication
TemozolomideApprovedSmall moleculeDNA alkylation (O6-guanine)Partial signal
NCT00626990: Overall survival: adjuvant temozolomide vs none, median 82.3 vs 46.9 months, hazard ratio 0.64 (95% CI 0.52 to 0.79), p<0.0001; concurrent temozolomide vs none, 66.9 vs 60.4 months, hazard ratio 0.97 (95% CI 0.73 to 1.28), p=0.76 (CT.gov posted results).
TrametinibApprovedSmall moleculeMEK1/2not yet gradedNo reviewed efficacy summary in this indication
LuvometinibPhase 3Small moleculeMEK1/2not yet gradedNo reviewed efficacy summary in this indication
SafusidenibPhase 3Small moleculeMutant IDH1not yet gradedNo reviewed efficacy summary in this indication
Abemaciclib (Verzenio)Phase 2Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
OlutasidenibPhase 2Small moleculeMutant IDH1not yet gradedNo reviewed efficacy summary in this indication
CrelosidenibPhase 1Small moleculeMutant IDH1 and IDH2not yet gradedNo reviewed efficacy summary in this indication
VebreltinibPhase 1Small moleculeMETnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tovorafenib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
March 2027 (2)
Phase 2Craniopharyngioma, Child, Craniopharyngioma, Recurrent CraniopharyngiomaRecruiting
Est. primary completion 2027-03-01 · NCT05465174 · CT.gov ↗
What to watch
Phase 1GliomaRecruiting
Est. primary completion 2027-03-21 · NCT06381570 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2GliomaRecruiting
Est. primary completion 2027-05-31 · NCT04775485 · CT.gov ↗
What to watch
June 2027 (1)
Phase 3GliomaActive not recruiting
Est. primary completion 2027-06 · NCT05566795 · CT.gov ↗
What to watch
2028 (1)
September 2028 (1)
Phase 2Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell HistiocytosisRecruiting
Est. primary completion 2028-09-30 · NCT05828069 · CT.gov ↗
What to watch
2030 (3)
February 2030 (1)
Phase 2GliomaNot yet recruiting
Est. primary completion 2030-02 · NCT07206849 · CT.gov ↗
What to watch
March 2030 (1)
Phase 1/2Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell LeukemiaRecruiting
Est. primary completion 2030-03-01 · NCT06965114 · CT.gov ↗
What to watch
July 2030 (1)
Phase 1GliomaActive not recruiting
Est. primary completion 2030-07-31 · NCT07441707 · CT.gov ↗
What to watch

See the full readout calendar ↗